Literature DB >> 8315481

Studies with positron emission tomography after systemic administration of fluorine-18-uracil in patients with liver metastases from colorectal carcinoma.

A Dimitrakopoulou1, L G Strauss, J H Clorius, H Ostertag, P Schlag, M Heim, F Oberdorfer, F Helus, U Haberkorn, G van Kaick.   

Abstract

Fluorouracil (FU) is the most common cytostatic agent used for chemotherapy in patients with colorectal tumors. Fifty patients with 78 hepatic metastases from colorectal tumors were examined with positron emission tomography (PET) following intravenous infusion of 18F-FU. The uptake of the cytostatic agent was evaluated in normal liver parenchyma, liver metastases and the aorta. Tracer uptake was expressed with the standardized uptake value (SUV). The maximum liver activity was 11.3 SUV (mean value) with a standard deviation of 1.85 SUV. The highest activity concentrations were noted 30 min (mean value) postinjection. In comparison, the activity concentration of individual metastasis was low. Two hours after tracer injection, the mean activity in metastases was 1.3 SUV, but notable individual variation in uptake was seen. Fluorine-18 concentration values 2 hr after FU infusion were approximately 44% of the FU uptake 20 min postinfusion. Fifty-three metastases were also examined with 15O-labeled water. The examination was performed to compare the uptake of the nonmetabolized tracer with FU uptake. We noted a statistically significant correlation between 15O-water concentration, uptake of nonmetabolized FU 8 min after the end of the infusion and FU retention (120 min postinjection) in a subgroup of metastases. The results suggest that FU retention in different metastases is highly variable and mainly dependent on early FU uptake into tumor cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8315481

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  10 in total

Review 1.  Positron emission tomography (PET): expanding the horizons of oncology drug development.

Authors:  Lisa A Hammond; Louis Denis; Umber Salman; Paul Jerabek; Charles R Thomas; John G Kuhn
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

Review 2.  Molecular imaging in clinical trials.

Authors:  Debra Josephs; James Spicer; Michael O'Doherty
Journal:  Target Oncol       Date:  2009-09-21       Impact factor: 4.493

3.  Limited value of positron emission tomography in treatment of pancreatic cancer: surgeon's view.

Authors:  R K Kasperk; K P Riesener; K Wilms; V Schumpelick
Journal:  World J Surg       Date:  2001-09       Impact factor: 3.352

Review 4.  Positron emission tomography to assess hypoxia and perfusion in lung cancer.

Authors:  Eline E Verwer; Ronald Boellaard; Astrid Am van der Veldt
Journal:  World J Clin Oncol       Date:  2014-12-10

5.  Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas.

Authors:  A Dimitrakopoulou-Strauss; L G Strauss; H Goldschmidt; W J Lorenz; W Maier-Borst; G van Kaick
Journal:  Eur J Nucl Med       Date:  1995-05

Review 6.  Fluorinated tracers for imaging cancer with positron emission tomography.

Authors:  Olivier Couturier; André Luxen; Jean-François Chatal; Jean-Philippe Vuillez; Pierre Rigo; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-06       Impact factor: 9.236

7.  Serum albumin (SA) accumulation by bronchogenic tumours: a tracer technique may help with patient selection for SA-delivered chemotherapy.

Authors:  J H Clorius; H Sinn; H G Manke; H H Schrenk; J Blatter; C Werling; E A Friedrich; J Voges; M Bahner; V Sturm
Journal:  Eur J Nucl Med       Date:  1995-09

Review 8.  The role of DNA synthesis imaging in cancer in the era of targeted therapeutics.

Authors:  Sridhar Nimmagadda; Anthony F Shields
Journal:  Cancer Metastasis Rev       Date:  2008-12       Impact factor: 9.264

Review 9.  Approaches using molecular imaging technology -- use of PET in clinical microdose studies.

Authors:  Claudia C Wagner; Oliver Langer
Journal:  Adv Drug Deliv Rev       Date:  2010-09-29       Impact factor: 15.470

10.  A Transmetalation Reaction Enables the Synthesis of [18F]5-Fluorouracil from [18F]Fluoride for Human PET Imaging.

Authors:  Andrew J Hoover; Mark Lazari; Hong Ren; Maruthi Kumar Narayanam; Jennifer M Murphy; R Michael van Dam; Jacob M Hooker; Tobias Ritter
Journal:  Organometallics       Date:  2016-02-14       Impact factor: 3.876

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.